| ID Source | ID |
|---|---|
| PubMed CID | 6419976 |
| CHEMBL ID | 1315633 |
| CHEBI ID | 181427 |
| SCHEMBL ID | 968911 |
| Synonym |
|---|
| [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;hydrate |
| CHEBI:181427 |
| adenosine-5'-monophosphate monohydrate |
| PRESTWICK_546 , |
| adenosine 5'-monophosphate monohydrate , |
| 18422-05-4 |
| adenosine 5'-monophosphate monohydrate, from yeast, >=97% |
| adenosine 5'-monophosphate monohydrate, from yeast, >=99% |
| MLS001306420 |
| smr000718790 |
| HMS1569G13 |
| HMS2096G13 |
| ((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate hydrate |
| A812845 |
| HMS2232G19 |
| S5284 |
| AKOS025310791 |
| CCG-220356 |
| 5'-adenylic acid, hydrate (1:1) |
| SCHEMBL968911 |
| CHEMBL1315633 |
| mfcd00149360 |
| 5'-amp monohydrate |
| sr-01000837507 |
| SR-01000837507-2 |
| adenosine-5'-phosphate monohydrate |
| HMS3713G13 |
| CS-8159 |
| HY-A0181A |
| 9-(5-o-phosphonopentofuranosyl)-9h-purin-6-amine--water (1/1) |
| DTXSID00939806 |
| adenosine 5'-monophosphate monohydrate; 5'-adenylic acid;5'-amp |
| F85584 |
| adenosine 5-monophosphate monohydrate |
| Class | Description |
|---|---|
| purine ribonucleoside monophosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acid sphingomyelinase | Homo sapiens (human) | Potency | 44.6684 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 32.6427 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 35.4813 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 5.1682 | 0.8913 | 10.4328 | 20.5750 | AID2265; AID2530 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 8.8355 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722; AID2559 |
| IDH1 | Homo sapiens (human) | Potency | 16.3601 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 6.3752 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634; AID2263 |
| geminin | Homo sapiens (human) | Potency | 0.1158 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 3.5481 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0388 | 14.3501 | 43.6206 | AID2676 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 0.7943 | 12.2693 | 31.6228 | AID2263 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.1623 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 2.2387 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Potency | 6.5064 | 5.7988 | 6.2705 | 6.5064 | AID2263 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 31.6228 | 0.0757 | 8.4742 | 29.0628 | AID602233 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Phospholipase C, gamma 1 | Homo sapiens (human) | IC50 (µMol) | 13.2120 | 1.2120 | 3.1662 | 6.3720 | AID743329 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glycogen synthase kinase-3 beta isoform 1 | Homo sapiens (human) | EC50 (µMol) | 300.0000 | 0.2125 | 22.1562 | 83.9400 | AID434954 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||